Furthermore, when used at a dose of 300 μg per injection for each mouse, anti-PD-1 (an immune checkpoint inhibitor (ICI) targeting T cells), significantly suppressed the growth and incidence of subcutaneously grafted CT26.CL25 cells, a beta-galactosidase expressing subclone of CT26.WT widely used for testing immunotherapy protocols and host immune response18, in control diet-fed but not MR diet-fed Balb/c mice (Fig. 2g and Supplementary Fig. 1a), indicating that MR reduces the efficacy of ICIs. This evidence concerns the gene PDCD1 and miotic rate.